Skip to main content

Carboplatin Pregnancy and Breastfeeding Warnings

Carboplatin is also known as: Carboplatin Novaplus, Paraplatin

Carboplatin Pregnancy Warnings

Animal studies have revealed evidence of mutagenesis, embryotoxicity, and teratogenicity. There are no controlled data in human pregnancy. It is not known whether this drug can cause fetal harm or adversely affect reproductive capacity in humans.

AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

US FDA pregnancy category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Use is not recommended; according to some experts, use is contraindicated.

AU TGA pregnancy category: D
US FDA pregnancy category: D

-This drug can harm a developing fetus.
-Adequate methods of contraception should be encouraged.
-If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

See references

Carboplatin Breastfeeding Warnings

Use is not recommended; according to some experts, use is contraindicated.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

-The effects in the nursing infant are unknown.
-Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.
-Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing.

Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as this drug. It might be possible to breastfeed safely during intermittent therapy with an appropriate period of breastfeeding abstinence, but the duration of abstinence is not clear. In one case, carboplatin was still detectable in milk 13 days after a dose of 2.9 mg/kg.

See references

References for pregnancy information

  1. "Product Information. Carboplatin (carboplatin)." Sun Pharmaceutical Industries (2019):

References for breastfeeding information

  1. "Product Information. Carboplatin (carboplatin)." Sun Pharmaceutical Industries (2019):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.